Physiologic role oferythropoietin in erythroid differentiation Erythropoietin (EPO)' is a 34-kD glycoprotein hormone which is the primary regulator of human erythropoiesis. A cDNA encoding EPO has been isolated (1) , and recombinant EPO with oligosaccharide moieties identical to the natural material is available (2) . EPO is synthesized and released by the kidney, and it circulates to the bone marrow where it stimulates resident erythroid progenitors via a specific receptor (3) . EPO as a pharmacologic agent has clearly demonstrated efficacy in anemic states such as kidney failure (4, 5) . In vivo, EPO causes a rapid rise in hematocrit in 7-10 d.
Despite the availability of purified recombinant EPO, little is known regarding the interaction of EPO and the erythropoietin receptor (EPO-R) or the physiologic mechanisms by which EPO causes cells to undergo proliferation or differentiation. This is largely due to the lack of adequate quantities of EPO-R for in-depth biochemical study. Only small numbers of surface EPO-R (< 1,000) are present on normal erythroblasts and erythroleukemia cells. EPO provides a proliferative signal to the Burst-forming unit-erythroid (BFU-E), an early EPOresponsive erythroid progenitor, and a differentiative signal to the colony-forming unit-erythroid (CFU-E), a later EPO-responsive erythroid progenitor (3) . These two classes of EPOresponsive cells are clearly different populations since they can be separated by unit gravity sedimentation and more recently have been purified to homogeneity (6) . The purpose of this review is to describe the recent advances in our understanding of EPO-R the studies described used iodinated recombinant human EPO. Scatchard analysis has been employed to determine the number of binding sites per cell and the affinity constants for the interaction. As shown in Table I (references 6-37), -200 EPO-R are present on the cell surface of purified normal erythroid progenitors. On certain cell lines, that number can increase to about 1,000 per cell. This relatively low number of EPO-R is characteristic of other receptors for hematopoietic cytokines such as G-CSF, GM-CSF, IL-3, and IL-6 (reviewed in references [38] [39] [40] . Scatchard analysis revealed that certain erythroid cells, such as MEL cells, express only low-affinity receptors whereas other cell lines express high-and low-affinity receptors (Table I) . Of note, the lower-affinity receptor has an affinity constant in the 200 pM range and therefore still represents an intimate interaction between receptor and ligand. Although functional differences between the higher-and loweraffinity EPO-R have not been determined, the two affinities may account for different cellular responses to EPO. Friend virus-infected cells respond to EPO with proliferation and differentiation. MEL cells bind EPO only with low affinity and do not appear to respond to the hormone. Affinity cross-linking experiments using radiolabeled EPO (Table I) (Fig. 1) . As expected, the EPO-R transcript showed erythroid specific expression (41) . Surprisingly, the COS cell transfectants, unlike MEL cells, demonstrated both high-and low-affinity receptors (Fig. 2 A) . This result suggested that the cDNA encoded one subunit of the EPO-R, and that a second subunit, or accessory protein, was endogenous to COS cells. The COS cell transfectants also demonstrated two cross-linked com- plexes (Fig. 2 B) . These cross-linked complexes were similar in molecular weight to those observed in normal erythroid progenitor cells (Table I) .
A new growth factor receptor superfamily
The EPO-R was initially found to have extensive amino acid homology with the interleukin 2 receptor, chain (42 (47, 48) , the IL-6 receptor (49), the GM-CSF receptor (50) , and the prolactin and growth hormone receptor (51) . The most striking similarity among all members of this cytokine receptor superfamily includes the conservation of four cysteines and a tryptophan-serine-X-tryptophan-serine motif positioned just outside the transmembrane region. These sequence homologies probably reflect structural homologies among these receptors. The receptor structural homologies may extend to structural homologies among the respective growth factors themselves. The crystal structure of growth hormone reveals an antiparallel four-helix bundle core. Modeling of the tertiary structure of EPO and IL-6 also reveals a growth hormone-like helix bundle fold (J. F. Bazan, personal A. EPO As discussed previously, the major difficulty encountered in studies of EPO-induced signal transduction has been the small number of surface receptors and the unavailability of a purely EPO-dependent cell line. The EPO-R, although expressed in high numbers in COS cell transfectants (41) , is not functional in these cells. The addition of EPO to these transfectants does not change the growth kinetics of the cells or induce erythroid differentiation (D'Andrea, A., unpublished observation). In contrast, transfection of the EPO-R cDNA into Ba/F3 cells, a murine cell line dependent on the hormone, interleukin 3 (multi-CSF), does confer EPO dependence (57, 58 ). An EPO-dependent clone of Ba/F3 cells (Ba/F3-EPO-R) has been isolated which expresses cell surface EPO-R and which has absolute dependence on EPO for growth. The availability of this homogeneous, EPO-dependent cell line should greatly facilitate the study of the EPO-R structure and signaling mechanisms. anchor. The interaction between the EPO-R and gp55 could occur at several different sites along the molecules (Fig. 4) and in several possible subcellular compartments. Through direct binding of the EPO-R, gp55 can stimulate the receptor and bypass the normal requirement for EPO, causing a prolonged proliferation of infected erythroid cells. The gp55 may mimic EPO itself, although there is no amino acid homology shared between these two proteins. Alternatively, gp55 may have sequences derived from (and therefore mimic) the normal cellular second subunit of the EPO-R. The interaction between the EPO-R and gpS5 is also observed in MEL cells (58) and probably accounts for the absence of high-affinity binding sites on MEL cells and for the EPO unresponsiveness of these cells (41) . Recent evidence suggests that the interaction between the EPO-R and the gp55 occurs within the endoplasmic reticulum (58, 64) . Also, the interaction of these two proteins is a novel mechanism of viral transformation leading to growth factor independence. It is possible that analogous retroviruses transform other cell types using, for instance, the IL-2 receptor or the IL-3 receptor, other members of the EPO-R superfamily.
Interaction ofthe EPO-R with the Friend virus gp55
Since the EPO-R is a member of a large hematopoietic growth factor superfamily, any molecular insight into the EPO-R subunit structure, the generation of its multiple affinities for EPO, or its signaling mechanism may be generalizable to the other family members. Recent insight is derived from the observation that the EPO-R binds to and is activated by the membrane glycoprotein, gp55, of the Friend spleen focus-forming virus (SFFV) (58) . SFFV is a defective murine C-type retrovirus that causes a multistage erythroleukemia in mice and erythroblastosis in bone marrow cultures (59, 60) . The SFFV env gene encodes a membrane glycoprotein, gp55, that is located on the cell surface and within rough endoplasmic reticula (61) and that is essential for the induction of leukemia in vivo (62) and the erythropoietin-independent erythroblast proliferation in vitro (63) . By co-transfecting both EPO-R and the gp55 into an interleukin-3-dependent lymphocyte cell line, it was shown that the physical interaction of these two proteins gives rise to autocrine cell growth. The interaction between the EPO-R and gp55 is shown schematically in Fig. 4 There are two classes of human diseases that, theoretically, could result from defects in the EPO-R. First, the EPO-R may have a role in the pathogenesis of pure red cell aplasia including congenital aplastic anemia (so-called Diamond-Blackfan anemia) (65, 66) . With the availability of the human cDNA and gene for the EPO-R (67) and antisera which recognize the normal human EPO-R polypeptide (67), the possible role of EPO-R in the pathogenesis of these anemias will be testable.
This will lead to better classification of anemias and could lead to more tailored therapies. Although the EPO-R gene has recently been localized to human chromosome 19p (68) , no human diseases suggestive of EPO-R pathology map to this region.
Secondly, polycythemia vera (PV) may be caused by an acquired change in the EPO-R. PV is a human myeloproliferative disorder characterized by an expansion of all three major hematopoietic cell types in peripheral blood and bone marrow, with the major clinical feature being an expanded red cell mass in the setting of low serum EPO levels (69) . Erythroid colonies (BFU-E and CFU-E) from bone marrow of PV patients may be grown in semisolid medium in the absence of exogenous EPO whereas growth of such progenitors from normal bone marrow is absolutely dependent on the presence ofEPO. Interestingly, radiolabeled EPO binding performed with bone marrow from PV patients reveals only a low-affinity receptor (70), a physiological state reminiscent of MEL cells which co-express the Friend SFFV gp55 and the EPO-R. It is quite possible that the molecular mechanism of PV, involving the loss of the high-affinity EPO-R, will be similar to the constitutively activating mechanism in mouse erythroblasts, induced by the physical association of the gp55 and the EPO-R. It is possible that bone marrow cells from PV patients express a viral or host protein which constitutively activates the endogenous EPO-R.
The recent cloning ofthe EPO-R and the recognition ofthe new cytokine receptor family will allow a more directed approach to studying EPO-induced signal transduction. Before the cloning of EPO-R, several conflicting studies addressed the question ofpossible second messengers. The EPO-R has significant amino acid homology (35%) in the cytoplasmic domain with the IL-2R (p75) and the IL-3R, receptors recently shown to transduce signaling through tyrosine phosphorylation. For instance, the IL-2R (p75) subunit activates a tyrosine kinase activity and the p75 subunit is itself tyrosine phosphorylated (71) . It is possible that the cytokine receptors are noncovalently associated with a tyrosine protein kinase in a manner similar to that observed with the T cell surface antigen, CD4 (72, 73) . The cytoplasmic homology of the EPO-R with these other receptors strongly argues for protein phosphorylation as an early component of transmembrane signaling. Also, because the EPO-R, transfected into IL-3-dependent cells, confers EPO dependence on these cells, a common pathway of signaling is likely to be found for these receptors and for other receptors in the cytokine receptor superfamily.
